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cancer. The mRNA level of AKAP12α gene was examined by reverse 
transcription-polymerase chain reaction (RT-PCR) in ten lung cancer 
cell lines. The mRNA level of AKAP12α gene was reduced in 6 of 10 
(60%) lung cancer cell lines. The AKAP12α expression was restored 
after treatment with the demethylating agent 5-aza-2’-deoxycytidine 
in lung cancer cell lines which have downregulated mRNA level of 
AKAP12α gene. This result was further substantiated by a luciferase 
reporter assay, showing the restoration of promoter activities when 
transfected with unmethylated AKAP12α promoter. The methyla-
tion status of CpG island 1 and 2 existed in the AKAP12α promoter 
was analyzed by performing bisulﬁte-sequencing analysis in ten lung 
cancer cell lines, forty six lung cancer tissues and matched normal 
tissues. Methylation of CpG island 1 in the AKAP12α promoter was 
detected in 30% of the lung cancer cell lines, whereas methylation of 
CpG island 2 in the AKAP12α promoter was observed in the immor-
talized bronchial cell line and in all the lung cancer cell lines. In all 
of the lung tumors, the CpG island 1 in the AKAP12α promoter was 
infrequently methylated. However, CpG island 2 in the AKAP12α 
promoter was highly methylated in lung tumors compared with the sur-
rounding normal tissues, and this was statistically signiﬁcant (p=0.002). 
Also, the analysis in the methylation level of CpG island 2 and the 
patient’s clinicopathological features was showed that the CpG island 2 
methylation of AKAP12α gene in male, non-recurrence subgroup was 
occurred more frequently than other subgroup. In summary, epigenetic 
AKAP12α silencing seems to be a relevant mechanism of inactivat-
ing this AKAP12α gene in lung cancer and the methylation rate of 
AKAP12α promoter is associated with lung cancer.
This study was supported by a grant of the Ministry of Health & Wel-
fare, Republic of Korea: A010250
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Introduction: Researches of cancer have two ways, in vivo and in vitro. 
Most of them are in vitro and their results are promising. However, us-
ing their results to in vivo had been disappointed because tumor contains 
3 dimensional structure, complicated components, and intercellular 
and/or cell/matrix interactions. Multicellular tumor spheroids (MCTS) 
is a kind of new research area of biology but lack of stromal cells and 
tumor associated macrophages. Artiﬁcial organisms, which have similar 
cell components compare with tumor, will be more complicated and 
advanced model than MCTS. We tried making a multicomponent mul-
ticellular tumor spheroids (MMCTS) from 3 kinds of cells from cancer 
cell from cancer cell line, ﬁbroblasts and peripheral blood mononuclear 
cells(PBMC) from human as a models to cancer research.
Method: A549 cell line, ﬁbroblasts cultured from human, and PBMC 
were cultured on rotatory cell culture system (RCCS) singly or com-
bined in DME media. Their formation of spheroids were observed 2 
times a week by inverted microscope and got samples serially for 4 
weeks. Cell components from combined spheroids were stained immu-
nohistochemically by antibody to cytokeratin, ﬁbroblast and CD68. 
Result: Cells, cultured singly, were aggregated and formed clusters 
except PBMC within a few days and formed spheroids between 4 to 
7 days. Fibroblasts were formed earlier than A549. The mixed cluster 
with A549, ﬁbroblast and PBMC were also formed round shape. Immu-
nohistochemical stain showed that cells from MMCTS preserved their 
characteristics for 4 weeks. 
Conclusion: MMCTS will be a new model for tumor research.
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Design: We investigated histopathological differentiation-associated 
proteins (HD proteins) of non-small cell lung cancer (NSCLC) using 2 
dimensional polyacrylamide gel electrophoresis (2DE) and attempted 
to classify NSCLC. We applied Ettan-DIGE system to 2DE analysis 
and investigated HD proteins on a single 2DE gel to compensate for the 
unfavorable reproducibility of 2DE analysis.
Materials and Methods: We collected samples for 2-DE from repre-
sentative histological types of primary lung cancer, such as squamous 
cell carcinoma, adenocarcinoma and small cell carcinoma between 
2003 and 2005. We selected 8 cases of well or moderately differenti-
ated squamous cell carcinoma conﬁrmed postoperativly to posses 
typical histological features of primary lung squamous cell carcinoma. 
The mixture that contained equal amount of these eight samples was 
regarded as a standard sample of lung squamous cell carcinoma (Sq 
standard sample). In the same way we selected 8 cases of well or mod-
erately differentiated adenocarcinoma to prefers a standard sample of 
primary lung adenocarcinoma (Ad standard sample). We also mixed all 
four cases of small cell carcinoma samples which were collected during 
these periods, and preferred a mixture as a standard sample of small 
cell carcinoma (Sm standard sample). Each standard sample of repre-
sentative histopathological types of primary lung cancer was labeled 
with 400 pmol of a ﬂuorescent dye (either Cy2, Cy3 or Cy5) per 50 µg 
protein according to the manufacturer’s protocol (GE Healthcare Bi-
osicences). Furthermore, using mass spectrometry we identiﬁed protein 
molecules that were detected in 2DE analysis, followed by validation 
analysis by immunohistochemistry.
Results: We detected 7 spots associated with squamous cell carci-
noma, 9 spots associated with adenocarcinoma and 13 spots associated 
with neuroendocrine carcinoma (NE-associated spots) on 2DE gel, 
and succeeded in identifying all histopathological associated proteins 
except three NE-associated proteins (Figure 1, Table 2). Of 29 identi-
ﬁed proteins in this investigation 8 were cytokeratin (CK), which were 
CK5, CK6A, CK8, CK6C, CK6D, CK17, CK18 and CK19. CK5, 
CK6A, CK6C, CK6D and CK17 were identiﬁed as a Sq-associated pro-
tein, and also CK8, CK18 and CK19 were identiﬁed as Ad-associated 
protein. The other identiﬁed proteins we recognized contained napsin 
A and annexin A4. We tried to validate the expression of various kinds 
of CK using immunohistochemical analysis. In CK5, CK5/6 and CK17 
the expression levels in squamous cell carcinoma were greater than in 
the other histopathological types. On the other hand, the expression 
levels of CK8 and CK18 in adenocarcinoma were greater than the other 
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS514
histopathological types. On immunostaining expression pattern of CK 
in large cell carcinoma was similar to that of adenocarcinoma.
Conclusion: The investigations of CK expression give us additional 
information concerning histopathological differentiation of primary 
lung cancer. Though more investigations are needed, there is a strong 
possibility that classiﬁcation based upon proteomic analysis, as well 
as morphological features, may reﬂect the biological characteristics of 
tumor cells.
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Introduction: Alterations in whole-body iron metabolism are known 
to occur in patients with cancer. Iron could participate in carcinogenesis 
and overabundance of iron is associated with increased risk of neopla-
sia at the site of metal deposition. 
Aim: The relationship between the iron status and survival of lung 
cancer patients and the expression of transferrin receptors 1 (TfR1) and 
ferritin in tumor tissue, tumor stroma and normal lung were studied. 
Patients and Methods: These ﬁndings were correlated with tumor 
type and clinical outcome in 111 male patients. Iron metabolism and 
inﬂammation parameters were determined by automated laboratory 
measurements at the time of diagnosis. TfR1 and ferritin expression 
were determined by immuno-histochemical methods on cancer tissue, 
tumor stroma and on the surrounding normal lung tissue. 
Results: More than ﬁfty percentages of patients survived less than 12 
months. At the time of diagnosis approximately a half of the patients 
had mild anemia of chronic disease and signiﬁcantly elevated serum 
ferritin. Nonspeciﬁc laboratory markers of inﬂammation were present. 
Tumor tissue expressed much more TfR1 and ferritin than the tumor 
stroma and normal lung tissue. The expression of TfR1 and the ferritin 
content in tumor tissue depended on the carcinoma type. TfR1 and the 
ferritin content in tumor tissue did not show correlation with systemic 
parameters of most of iron metabolism parameters. Strong ferritin ex-
pression in tumor tissue correlates only with lower transferin saturation.
Conclusion: Higher expression of ferritin in tumor tissue is not the re-
sults of higher body iron accumulation. Elevated serum ferritin in lung 
cancer patients is results of inﬂammation and oxidative stress rather 
than body iron overload. 
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Introduction: For some years, NSE has been known as a marker of 
choice for small cell lung cancer. However, its diagnostic sensitivity 
and speciﬁcity are not completly satisfactory, due to relatively high 
false negative rate in SCLC patients with limited disease and false posi-
tive rate in patients with non-malignant lung disease and non-small cell 
lung cancer. Recently, the usefulness of pro-gastrin-releasing peptide 
(ProGRP) as a tumor marker for SCLC has been investigated. Although 
the diagnostic sensitivity and speciﬁcity of ProGRP was found to be 
higher than serum NSE, only small number of data concern its utility 
in disease therapy monitoring and its value in prediction of response 
to treatment. The aim of the study was the evalutation of ProGRP and 
NSE levels at the time of diagnosis and during chemo- and radiothera-
py of SCLC patients with limited disease in respect to their prognosis.
Material and Methods: Studies of NSE and ProGRP were performed 
in a group of 52 SCLC-LD. Patients with SCLC with limited disease 
were treated simultaneously with chemo and radiotherapy. All of them 
also received prophylactic cranial irradiation between fourth and ﬁfth 
course of chemotherapy. The increment ratio of tumor markers was 
calculated as serum concentration divided by the cut off, for assessment 
of prognostic value of these markers.
Results: ROC curve analysis conﬁrmed that ProGRP was a better than 
NSE tumor marker for diagnostics of SCLC-LD patients ( Area under 
curves ROC: 0.935 vs. 0.789, p = 0.000). 
There were observed signiﬁcant differences in the frequency of 
elevated NSE and ProGRP levels before each course of chemotherapy 
and 3 months after its ﬁnishing, respectively:1st 57.6% vs. 78.8%, 2nd 
5.8% vs. 67.3%, 3th 0% vs. 36.5%, 4th 1.9% vs. 21.2%, in restaging 
6.7% vs. 15.7%. Changes in NSE levels during therapy were more in-
tensive than for ProGRP what was reﬂected in tumor markers half-life 
(NSE: 4.6 - 11 days; ProGRP: 19-28 days) as well as in the frequency 
of increment of tumor markers ratio values. Patients with tumor marker 
levels 2 times exceeding NSE cut off and 12.5-times ProGRP cut off 
before treatment, and those with NSE and ProGRP having these ratio 
values higher than 0.4 and 0.65 during restaging 3 months after ﬁnish-
ing therapy has shown worse prognosis. 
Multivariate analysis conﬁrmed that independent prognostic factors in 
SCLC with limited disease were: NSE level exceeding 2-times cut off 
value before treatment as well as NSE threshold 0.4 cut off and 0.65 
ProGRP cut off value 3 months after therapy.
Conclusions: 
1 Changes of ProGRP during combined therapy of SCLC-LD seem to 
be more adequate to actual clinical status of patients than NSE
2. NSE before treatment is a better than ProGRP prognostic factor in 
SCLC-LD patients however after ﬁnishing therapy both markers 
have similar predictive value
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Background: Low levels of circulating cell-free DNA are present in 
normal individuals. In cancer patients, much higher levels of circulating 
DNA are found. Importantly, circulating DNA in lung cancer patients 
demonstrates genetic alterations typical of the tumour, leading to interest 
in plasma and serum DNA for early clinical diagnosis, prognosis and 
disease monitoring. There is considerable variation among studies in the 
reported levels of circulating DNA and its characteristics, which may be 
attributable to differences in selection of the patient and control groups, 
and the methods used for DNA extraction and estimation of circulating 
DNA concentrations. Here, we compare the efﬁciency of different meth-
ods for extracting low-level circulating DNA from blood samples.
